Sudarshan Pharma Industries Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)
Sudarshan Pharma Industries Ltd · Financial Result · 30 Oct 2026, 3:56 am
Sudarshan Pharma Industries Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 21,697 (+28.5% YoY | +24.4% QoQ) ■ EBITDA: 2,058 (+123.6% YoY | +29.4% QoQ) ■ EBITDA Margin (%): 9.5 (+404 bps YoY | +37 bps QoQ) ■ PAT: 809 (+93.3% YoY | +38.1% QoQ) ■ EPS (INR): 0.31 (+93.8% YoY | +34.8% QoQ)
Original exchange filing (PDF)
More announcements from Sudarshan Pharma Industries Ltd
- Pursuant to Regulation 30 and other applicable Regulations, if any, of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations''), we inform .... · 09 Nov 2026
- In terms of Regulation 30 read with Para A of Part A of Schedule III to the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby submit the updated Investor .... · 07 Nov 2026
- In continuation of the Company''s letter dated 30/Oct/2026 (ref. no. SPIL/CS/2026-2027/72), the Board of Directors at its Meeting held on 29/Oct/2026 have approved the proposal to raising .... · 31 Oct 2026
- This is to inform you that the Board of Directors of the Company at its Board Meeting held on 29/Oct/2026 has approved the proposal to raising funds through issue and allotment of up to .... · 30 Oct 2026
- We are submitting herewith the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/Sep/2026 · 30 Oct 2026
- Sudarshan Pharma Industries Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Fund raising. · 29 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 and Fund Raising · 29 Oct 2026
- Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve i) Unaudited Standalone .... · 29 Oct 2026
